Cinqair (reslizumab): Basics, Side Effects & Reviews
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
NICE changes mind and backs new drug for severe asthma | Nursing Times
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Dosing and Administration
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
CINQAIR® (reslizumab) Injection – About Asthma Control
Teva files MAA for asthma treatment reslizumab
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
Reslizumab | New Drug Approvals
TA479 Review decision paper
Cinqair (reslizumab): Basics, Side Effects & Reviews
Reslizumab | Teva UK
FDA approves Teva's Cinqair (reslizumab) Injection
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
Medication Detail
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
FDA accepts Biological License Application for reslizumab
Brand name: Auvi-Q
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Attachment: Product Information: Reslizumab
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
